[go: up one dir, main page]

AR107212A1 - Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos - Google Patents

Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos

Info

Publication number
AR107212A1
AR107212A1 ARP160102016A ARP160102016A AR107212A1 AR 107212 A1 AR107212 A1 AR 107212A1 AR P160102016 A ARP160102016 A AR P160102016A AR P160102016 A ARP160102016 A AR P160102016A AR 107212 A1 AR107212 A1 AR 107212A1
Authority
AR
Argentina
Prior art keywords
sodium hyaluronate
solution
polymer
ionic
methylparaben
Prior art date
Application number
ARP160102016A
Other languages
English (en)
Inventor
Jai Velusamy
Kevin Drizen
Original Assignee
Glycobiosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54064127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR107212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glycobiosciences Inc filed Critical Glycobiosciences Inc
Publication of AR107212A1 publication Critical patent/AR107212A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones de matriz polimérica tópicas estables que comprenden concentraciones elevadas (de aproximadamente 1.5% p/p a aproximadamente 3.5% p/p) de hialuronato de sodio obtenido de una fuente de Streptococcus zooepidemicus y un polímero no iónico. La composición de matriz polimérica comprende además polietilenglicol y metilparabeno, y utiliza ingredientes que son de grado farmacéutico o farmacopeico. Las composiciones de matriz polimérica pueden comprender opcionalmente un ingrediente activo. Las composiciones de matriz polimérica tópicas se pueden usar en el tratamiento de heridas, quemaduras, ciertas condiciones dermatológicas, sequedad vaginal, y en la administración tópica y transdérmica y la liberación sostenida de ingredientes activos. Reivindicación 14: Un método para preparar una composición de matriz polimérica que comprende hialuronato de sodio bio-fermentado, polímero no iónico, polietilenglicol, metilparabeno, y agua, caracterizado porque comprende: a) añadir metilparabeno a agua y mezclar para producir una solución de metilparabeno, b) añadir hialuronato de sodio bio-fermentado a la solución de metilparabeno y mezclar para producir una solución de hialuronato de sodio, c) disolver por separado el polímero no iónico, opcionalmente hidroxietilcelulosa, en agua para producir una solución de polímero no iónico, d) combinar la solución de hialuronato de sodio con la solución de polímero no iónico y mezclar para producir una solución de polímero no iónico hialuronato de sodio homogénea, e) añadir polietilenglicol a la solución de polímero no iónico de hialuronato de sodio y mezclar para formar la composición de matriz polimérica, en donde el hialuronato de sodio bio-fermentado se proporciona en una cantidad de aproximadamente 1.5% p/p a aproximadamente 3.5% p/p y el polímero no iónico se proporciona en una cantidad de alrededor de 0.1% p/p a aproximadamente 2.0% p/p, y opcionalmente, en donde el método comprende además una etapa de añadir al menos un ingrediente activo, preferiblemente, en donde el ingrediente activo se selecciona de: ácido pantoténico, diclofenaco sódico, niacina y glicerina.
ARP160102016A 2015-07-03 2016-07-01 Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos AR107212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2896038A CA2896038C (en) 2015-07-03 2015-07-03 Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof

Publications (1)

Publication Number Publication Date
AR107212A1 true AR107212A1 (es) 2018-04-11

Family

ID=54064127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102016A AR107212A1 (es) 2015-07-03 2016-07-01 Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos

Country Status (12)

Country Link
US (2) US9821005B2 (es)
EP (1) EP3111925A1 (es)
KR (3) KR20180059748A (es)
CN (2) CN115025114A (es)
AR (1) AR107212A1 (es)
AU (1) AU2016289095B2 (es)
CA (1) CA2896038C (es)
CR (1) CR20180014A (es)
EC (1) ECSP17081071A (es)
MX (1) MX360365B (es)
SA (1) SA517390331B1 (es)
WO (1) WO2017004706A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018110607A1 (de) 2017-05-08 2018-11-08 Nvidia Corporation Verallgemeinerte Beschleunigung von Matrix-Multiplikations-und-Akkumulations-Operationen
CN111971387A (zh) 2018-07-25 2020-11-20 阿特根公司 新型透明质酸水解酶突变体和包含其的药物组合物
IT201900019762A1 (it) * 2019-10-24 2021-04-24 Fidia Farm Spa Composizione farmaceutica per uso nel trattamento della cistite di varia eziologia
CN115427562B (zh) 2020-08-07 2025-05-09 阿特根公司 制备重组玻尿酸酶的方法
CN113045773B (zh) * 2021-03-16 2022-05-31 南京林业大学 一种在兽疫链球菌发酵过程中原位诱导纳米纤维素凝胶化的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
NO161573C (no) 1983-11-25 1989-08-30 Miles Inc Fremgangsmaate til fremstilling av hyaluronsyre.
JPS60251898A (ja) * 1984-05-25 1985-12-12 Shiseido Co Ltd 醗酵法によるヒアルロン酸の製造方法
US4784990A (en) * 1985-01-18 1988-11-15 Bio-Technology General Corporation High molecular weight sodium hyaluronate
US4780414A (en) 1985-01-18 1988-10-25 Bio-Technology General Corp. Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus
US5023175A (en) * 1986-05-01 1991-06-11 Kabushiki Kaisha Yakult Honsha Novel production process of hyaluronic acid and bacterium strain therefor
GB9024223D0 (en) * 1990-11-07 1990-12-19 Fermentech Ltd Production of hyaluronic acid
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6063405A (en) 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
BR0215220A (pt) * 2001-12-21 2007-01-09 Novozymes Biopolymer As método para produzir um ácido hialurÈnico, célula hospedeira de bacillus, construção de ácido nucléico, seqüência de ácido nucléico isolada, vetor de expressão , vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, e, polipeptìdeo isolado
KR100927579B1 (ko) * 2006-12-13 2009-11-23 주식회사 엘지생명과학 히아루론산 및/또는 그것의 염을 함유하는 아토피성피부염의 개선 및 치료를 위한 조성물
WO2008094910A2 (en) * 2007-01-30 2008-08-07 Cypress Pharmaceutical, Inc. Hyaluronate compositions
CN102105133B (zh) * 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
CN103126974B (zh) * 2011-11-30 2018-04-10 王冕 一种凝胶剂
CN103254118A (zh) 2012-02-17 2013-08-21 温州大学 一种Hg2+探针的制备方法
JP6178412B2 (ja) * 2012-06-05 2017-08-09 オラテック セラピューティクス リミティド ライアビリティ カンパニー 炎症及び疼痛を治療するための医薬組成物
EP2983717A4 (en) * 2013-04-10 2016-04-13 Glycobiosciences Inc TOPICAL USEFUL COMPOSITION
CN103254448B (zh) * 2013-05-17 2015-06-24 成都金凯生物技术有限公司 一种医用透明质酸钠凝胶及其制备方法
CN103405470B (zh) * 2013-08-22 2016-08-10 北京泰克美高新技术有限公司 透明质酸和透明质酸盐在用于治疗和缓解口腔干燥的组合物的应用

Also Published As

Publication number Publication date
CN115025114A (zh) 2022-09-09
US20170020912A1 (en) 2017-01-26
MX2016008559A (es) 2017-04-25
CA2896038C (en) 2022-08-09
KR20180059748A (ko) 2018-06-05
CA2896038A1 (en) 2016-05-03
ECSP17081071A (es) 2018-04-30
EP3111925A1 (en) 2017-01-04
AU2016289095B2 (en) 2017-12-14
AU2016289095A1 (en) 2017-12-07
US9821005B2 (en) 2017-11-21
CN106309473A (zh) 2017-01-11
SA517390331B1 (ar) 2023-11-30
WO2017004706A1 (en) 2017-01-12
MX360365B (es) 2018-10-30
US10322142B2 (en) 2019-06-18
KR20230050475A (ko) 2023-04-14
CR20180014A (es) 2018-05-29
KR20210020171A (ko) 2021-02-23
US20180042957A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
AR107212A1 (es) Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos
ES2591030T3 (es) Composición farmacéutica antifúngica
AR063621A1 (es) Matriz polimerica insoluble en agua para la administracion de farmacos
BRPI0508933A (pt) composições para entrega tópica
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
GT201200069A (es) Formulaciones farmacéuticas muy concentradas
AR041913A1 (es) Formulaciones de deposito de liberacion controlada
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
AR063120A1 (es) Composiciones inyectables de deposito y proceso para prepararlas
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
MX2010004613A (es) Composicion topica.
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112020019875A8 (pt) composições tópicas para alívio da dor
BR112014016661A2 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112014016550A2 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
WO2013147577A1 (es) Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
PE20090387A1 (es) Formulacion de pasireotida
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
AR063111A1 (es) Una formulacion farmaceutica de taxano
UY32354A (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación
ES2880437T3 (es) Nuevas composiciones tópicas que comprenden ácido úsnico y su uso terapéutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure